Objective-Mendelian randomization studies revealed a causal role for remnant cholesterol in cardiovascular disease.
A fter lowering of low-density lipoprotein cholesterol (LDL-c) to recommended levels, a significant cardiovascular disease burden remains unaddressed. This residual risk has been attributed partly to triglyceride-rich lipoproteins, particularly in the nonfasting state. 1 In plasma, triglycerides are initially carried in very low-density-lipoproteins or chylomicrons. After lipolysis of triglycerides, triglyceride-rich lipoproteins are converted to "remnant" particles, enriched in cholesterol. 2 Recently, Mendelian randomization studies suggested a causal association between remnant cholesterol and ischemic heart disease. 3 The mechanisms contributing to the atherogenicity of remnant particles have been suggested to relate to subendothelial accumulation of remnant cholesterol (comparable to LDLc) or the induction of an inflammatory state. 4 In support of the latter, a causal association was reported between high remnant cholesterol and elevated C-reactive protein (CRP) levels. 5 The potential mechanisms by which remnant cholesterol particles may induce inflammatory changes remain to be established. Remnant cholesterol can be readily taken up by plaque macrophages without previous oxidation of the particle, 6 thereby promoting arterial inflammation. 7 This reaction propagates continued influx of circulating immune cells, predominantly monocytes, into atherosclerotic lesions in both experimental models 8 and patients, 9 leading to a multilevel inflammatory response. 10 Recent data support that remnant cholesterol can also be taken up by circulating monocytes, eliciting a proadhesive phenotype. 11 Upstream, this heightened activation status is likely to be maintained by augmented hematopoietic activity, as has been shown in patients with cardiovascular disease. 12 In this study, we evaluated the impact of elevated levels of remnant cholesterol on multi-level inflammatory activation in patients with familial dysbetalipoprotenemia (FD), a genetic disorder leading to the elevated levels of remnant cholesterol. 13 Inflammatory activity of the arterial wall and activity of the bone marrow were assessed using 18 F-fluordeoxyglucose positron emission tomography computed tomography ( 18 F-FDG PET/CT).
14 In parallel, we also assessed the phenotype of circulating monocytes using flow cytometry and remnantinduced changes in hematopoietic activity. Finally, we examined the association between remnant cholesterol levels and blood leukocyte counts in the CGPS.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Study Population
We included 17 patients with FD (age 60±8 years, 70% male) and 17 healthy controls matched for age and sex (age 61±8 years, 59% male). Baseline characteristics are listed in Table 1 
Increased Integrin Expression on Monocytes in Patients With FD
As postprandial lipids were previously found to induce skewing of monocytes toward a proinflammatory phenotype, 11 we also assessed monocyte phenotype in patients with FD. Using flow cytometry, we found that distribution of the proinflammatory classical monocyte (CD14 The baseline characteristics were based on the included patients with FD and healthy controls. Values are n, mean±SD or median (IQR) for non-normally distributed data. CRP indicates C-reactive protein; DBP, diastolic blood pressure; FD, familial dysbetalipoproteinemia; HDL, high-density lipoprotein; LDL, lowdensity lipoprotein; SBP; systolic blood pressure; and WBC, white blood cell count.
( Figure 2C and 2D), where elevated CD11c expression levels was observed in the intermediate monocyte subset (Figure 2E ).
Intracellular Lipid Accumulation
As it was previously suggested that increased integrin expression is the result of excessive intracellular lipid accumulation, 15 we assessed the lipid content of circulating monocytes in patients with FD using Nile Red lipid staining and highresolution confocal laser scanning microscopy. 
Patients With FD Show Enhanced Bone Marrow Activity and Leukocytosis
Murine data suggested that lipid accumulation in hematopoietic stem and progenitor cells (HSPCs) resulted in an expansion of the hematopoietic lineage. 16 We, therefore, assessed leukocyte counts and bone marrow activity in patients with FD and controls. As shown in Table 1 Figure 3A and 3B, 3C). Moreover, in patients with FD increased FDG uptake in the bone marrow correlated significantly to leukocyte counts (SUV mean r=0.577, r 
Validation in the Copenhagen General Population Study
To further substantiate our findings, we finally aimed to show a dose-dependent relationship between remnant cholesterol and circulating leukocytes. To this end, we determined the correlation of remnant cholesterol and leukocyte lineage count in the CGPS (Copenhagen General Population Study). Table 2 shows a significant association with leukocyte counts ranging from 6.8×10 
Discussion
Observational and Mendelian randomization studies revealed a strong, causal relationship between elevated levels of remnant cholesterol and CV-risk. 3 In this study, we provide the first human validation of several hypotheses underlying this association. We show that (1) with FD patients have increased arterial wall inflammation; (2) monocytes of these patients show increased intracellular lipid accumulation with a concomitant adhesive phenotype, as well as (3) an increased metabolic activity of the bone marrow in FD patients, with a corresponding increase in 
Lipid-Driven Atherogenesis
The trapping of apoB-containing lipoproteins in the arterial intimal space is the key initiating factor in the formation of atherosclerotic lesions. 17 Elevated LDL-c levels were previously associated with increased arterial wall inflammation. 18 Here we show that patients with elevated levels of remnant cholesterol, but low levels of LDL-c, are also characterized by increased arterial wall inflammation. In contrast to larger triglyceride-rich lipoproteins such as chylomicrons, triglyceride-rich lipoprotein remnant particles can enter the arterial wall. 4 This arterial retention will lead to enhanced plaque formation, whereas it has also been proposed to elicit an inflammatory response. 7, 19 Besides a local inflammatory effect in the arterial wall, we also report a marked increase of intracellular lipid accumulation in plasma monocytes, which coincided with increased expression of the integrins CD11b/CD11c/CD18 on the surface of circulating monocytes in patients with FD. These findings in patients with genetically determined, elevated remnant levels show a striking resemblance to those by Gower et al 11 , reporting increased expression of CD11c/CD18 on monocytes in healthy volunteers after consuming a highfat meal. These proadhesive changes were attributed to accumulation of lipids in circulating monocytes. 11 The relationship between remnant cholesterol accumulation and phenotypic changes in monocytes is supported by our in vitro findings, showing a dose-dependent increase in intracellular lipid accumulation, which is in line with proadhesive changes reported by Gower et all. 11 Xu et al 15 showed that these "foamy" monocytes promote the formation of atherosclerotic lesions in mice, whereas upregulation of CD11c is known to play a key role in the migration of these monocytes into the arterial wall. As it was recently shown that leukocytes also home toward atherosclerotic lesions in patients with atherosclerotic disease, 9 the proinflammatory phenotype of monocytes in subjects with elevated levels of remnant cholesterol can be expected to contribute to the increased arterial inflammatory activity that was found.
Hematopoiesis
Besides activation of circulating monocytes, we also observed an increased leukocyte count with a marked monocytosis in patients with FD. Experimental studies previously showed that apoE −/− mice exhibited excessive proliferation and myeloid skewing of HSPCs as a result of cholesterol trapping. 16 By lowering LDL-c in humans using statins, the number of circulating HSPCs is reduced, supporting the reversibility of LDL-associated bone marrow activation in humans as well. 20 In this study, we show increased metabolic activity ( 18 F-FDG PET/CT) in the bone marrow of patients with FD, correlating with plasma leukocyte number. In vitro, incubation of HSPCs with remnant cholesterol induced intracellular cholesterol accumulation. Together, these data suggest that remnant cholesterol may also induce increased proliferation at the bone marrow level. Interestingly, in addition to an overall increase in numbers, lipid accumulation may also induce early skewing toward the monocyte lineage, as suggested by the flow cytometry experiments. The robustness of this observation is underscored by the positive correlation between remnant cholesterol and hematopoietic activity in the CGPS. These findings in a large population-based cohort show that also in moderate phenotypes, fluctuations in remnant cholesterol affect the myeloid bone marrow-plasma axis, leading to elevated leukocyte numbers. Previous data from the CGPS reported causal associations between remnant cholesterol, ischemic heart diseases, and levels of low-grade inflammation using a Mendelian randomization approach, 5 which was attributed to the ability of remnant cholesterol to accumulate in plaque macrophages without prior oxidation. Our data substantiate this hypothesis by demonstrating the capability of remnant cholesterol to accumulate in immune cells in patients with FD, who also exhibit increased leukocyte levels and a proatherogenic phenotype of their circulating monocytes.
Limitations
Our study has several limitations. First, we studied a relatively modest number of patients with genetically determined levels of remnant cholesterol based on FD in a case-control design. However, this small group is well defined with high levels of remnant cholesterol and low levels of LDL-c, no diabetes mellitus or other conditions confounding the results, thereby enabling us to specifically address the impact of elevated remnant levels. Body mass index and systolic blood pressure were significantly different between patients with FD and healthy controls (dictated by the nature of the disease), but correction for these factors did not alter our findings. CRP was different as well; however, previous studies showed no correlation between CRP levels and arterial wall inflammation. 21, 22 Second, the definition of remnant cholesterol remains a matter of debate. Varbo et al 2 described remnant cholesterol as total cholesterol minus high-density lipoprotein cholesterol minus LDL-c, which is a readily applicable method. However, this simplified method also introduces the lack of particle specificity. Specific components of the remnant cholesterol particles predisposing to atherogenicity remain to be elucidated. Finally, the use of 18 F-FDG PET/CT to assess bone marrow activity has not been linked to a specific pathophysiological process in the bone marrow. Therefore, the use of increased FDG uptake as a marker of increased progenitor potential should be interpreted with caution. Conversely, the linear relationship between increased FDG-bone marrow uptake and circulating leukocyte levels supports this assumption in this study.
Clinical Implications
Although the population with FD is an extreme model, elevated levels of (nonfasting) remnant cholesterol are present in 38% of men and 20% of women in the general population, 23 emphasizing the importance of better understanding its relationship with cardiovascular disease. Our study provides important novel pathophysiological insights in the atherogenicity of remnant cholesterol, showing increased arterial inflammation and bone marrow activation in patients with elevated levels of remnant cholesterol. These findings indicate an important multilevel inflammatory component to the atherogenicity of remnant cholesterol, which may contribute to its relation with increased CV risk.
